New Obesity Drug Could Be Available in 6 Months
Orexigen resubmits its marketing application for Contrave, setting up a battle for the bulge with VIVUS and Arena Pharmaceuticals.
Orexigen Therapeutics: Light at the End of the Tunnel?
Orexigen Therapeutics announces successful interim results for its lead product candidate Contrave followed by the potentially share dilutive announcement of $100 million convertible senior notes offering. Which way should the stock go?
3 Horrendous Health-Care Stocks This Week
How poorly did Lexicon, Orexigen, and Ariad stocks perform this week? Bad enough to be the three worst health-care stocks in the land.
Arena Pharmaceuticals' Slow 2013
The showdown between Arena Pharmaceuticals and VIVUS in 2013 was much ado about nothing. Will Orexigen entering the obesity market in 2014 change things?
This New Data Shows We're on the Wrong Path to Treating Obesity
A new Gallup poll shows a disturbing trend in U.S. eating habits. Here's a look at what could be causing our poor eating habits and what needs to be done to turn this disease on its head.